Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SCOPUS BIOPHARMA INC.

(SCPS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/20/2021 07/21/2021 07/22/2021 07/23/2021 07/26/2021 Date
5.33(c) 5.35(c) 5.12(c) 4.7(c) 4.73(c) Last
45 059 75 085 62 149 333 837 146 076 Volume
-2.20% +0.38% -4.30% -8.20% +0.64% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -14,5 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,14x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -23,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -3,38x
Yield 2022 -
Capitalization 79,6 M 79,6 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 1
Free-Float 43,8%
More Financials
Company
Scopus BioPharma Inc. is a biotechnology company. The Company is focused on developing therapeutics targeting serious diseases. The CompanyÔÇÖs lead program targets immuno-oncology gene therapy for the treatment of multiple cancers. Its lead development program is CpG-STAT3siRNA (CO-sTiRNA), which is in Phase I clinical trial, is a STAT3 inhibitor gene therapy. CO-sTiRNA is developed for the treatment of B-cell... 
More about the company
All news about SCOPUS BIOPHARMA INC.
07/12SCOPUS BIOPHARMA : Announces New Management Appointment Following Acquisition of..
AQ
07/12Scopus BioPharma Announces New Management Appointment Following Acquisition o..
CI
07/09SCOPUS BIOPHARMA INC. : Change in Directors or Principal Officers (form 8-K)
AQ
07/09Scopus Biopharma Inc. Announces Termination of Ashish Sanghrajka from Board
CI
07/01SCOPUS BIOPHARMA INC. : Entry into a Material Definitive Agreement, Completion o..
AQ
06/30SCOPUS BIOPHARMA : Buys Oncology Firm Olimmune for Undisclosed Sum
MT
06/30Scopus BioPharma Expands Immunotherapy Pipeline with Acquisition of Olimmune
GL
06/30Scopus BioPharma Inc. acquired Olimmune Inc.
CI
06/25SCOPUS BIOPHARMA INC.(NASDAQGM : SCPS) dropped from Russell 3000E Index
CI
06/25SCOPUS BIOPHARMA INC.(NASDAQGM : SCPS) dropped from Russell 3000E Value Index
CI
06/25SCOPUS BIOPHARMA INC.(NASDAQGM : SCPS) dropped from Russell Microcap Value Index
CI
06/25SCOPUS BIOPHARMA INC.(NASDAQGM : SCPS) dropped from Russell 2000 Dynamic Index
CI
06/25SCOPUS BIOPHARMA INC.(NASDAQGM : SCPS) dropped from Russell 2000 Index
CI
06/25SCOPUS BIOPHARMA INC.(NASDAQGM : SCPS) dropped from Russell 2500 Growth Index
CI
06/25SCOPUS BIOPHARMA INC.(NASDAQGM : SCPS) dropped from Russell 2000 Value Index
CI
More news
News in other languages on SCOPUS BIOPHARMA INC.

- No features available -

More news
Analyst Recommendations on SCOPUS BIOPHARMA INC.
More recommendations
Chart SCOPUS BIOPHARMA INC.
Duration : Period :
Scopus BioPharma Inc. Technical Analysis Chart | SCPS | US8091711015 | MarketScreener
Technical analysis trends SCOPUS BIOPHARMA INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 4,73 $
Average target price 20,00 $
Spread / Average Target 323%
EPS Revisions
Managers and Directors
Ashish P. Sanghrajka President & Director
Joshua R. Lamstein Chairman
Raphael Hofstein Independent Director
Robert J. Gibson Vice Chairman, Secretary & Treasurer
Ira Scott Greenspan Director
Sector and Competitors
1st jan.Capi. (M$)
SCOPUS BIOPHARMA INC.-68.13%109
GILEAD SCIENCES, INC.18.01%85 134
WUXI APPTEC CO., LTD.32.49%71 226
REGENERON PHARMACEUTICALS19.60%57 013
BIONTECH SE251.15%55 555
VERTEX PHARMACEUTICALS-15.83%50 308